Navigation Links
InteKrin Therapeutics Announces $20 Million Series C Financing
Date:8/4/2008

LOS ALTOS, Calif., Aug. 4 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity today announced it has completed the first close of a Series C venture financing for $18.25 million. The financing was led by Skyline Ventures of Palo Alto, CA and Managing Director David Lowe Ph.D. of Skyline will join InteKrin's Board of Directors. Existing major investors Sofinnova Ventures and OrbiMed Advisors also significantly participated, as did other earlier investors. The Company anticipates a second close of the Series C bringing the total for the round to $20 million to support the continued development of INT131, a non-TZD selective modulator of PPAR gamma (SPPARM) for treatment of Type II diabetes (T2DM).

"InteKrin is very pleased to have Skyline, a premier health care venture firm, lead its Series C financing," remarked InteKrin's President and CEO Denny Lanfear. "This investment and the ongoing support of our existing investors including Sofinnova and OrbiMed will allow us to fully prepare INT131 for the initiation of the Phase 3 studies in 1H10 and maintain our rapid development pace."

"The nonclinical safety multiples seen with INT131 together with the strong efficacy seen in the Phase 2a study present a unique profile," commented Skyline Ventures' David Lowe Ph.D. "The biology of INT131 and its demonstrated ability to selectively modulate PPAR gamma promises to deliver to patients glucose lowering efficacy without the safety compromises of currently available insulin sensitizers."

INT131 was designed specifically to antagonize characteristic TZD adverse effects while retaining powerful PPAR gamma anti-diabetic efficacy, and represents a new product and chemical class. INT131 is well positioned to fulfill the unmet medical need for a safe treatment of insulin resistance, the key etiological feature in the onset and subsequent progression of T2DM and metabolic syndrome.

Phase 2a clinical efficacy data was presented in June 2008 at ADA and new nonclinical safety data will be presented next month at EASD. InteKrin's previously announced 360 patient, 24 week placebo controlled Phase 2b study with a 45mg Actos(R) comparator arm was initiated in February, 2008 and results are expected to be completed in 2H09.

About InteKrin (http://www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in- licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

To learn more about InteKrin, visit http://www.InteKrin.com.


'/>"/>
SOURCE InteKrin Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: